Ikarian Capital’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Ikarian Capital’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-136,059	Closed	-$95K	–	168
2023 Q1	$95K	Hold	136,059	–	–	0.02%	112
2022 Q4	$122K	Hold	136,059	–	–	0.03%	76
2022 Q3	$815K	Sell	136,059 -517,389	-79%	-$2.93M	0.16%	74
2022 Q2	$2.7M	Hold	653,448	–	–	0.49%	50
2022 Q1	$2.48M	Buy	653,448 +24,064	+4%	+$108K	0.33%	58
2021 Q4	$2.83M	Hold	629,384	–	–	0.42%	51
2021 Q3	$2.93M	Sell	629,384 -14,672	-2%	-$77.7K	0.21%	108
2021 Q2	$4.54M	Sell	644,056 -32,238	-5%	-$174K	0.37%	73
2021 Q1	$4M	Buy	+676,294	New	+$4.1M	0.13%	141
2020 Q3	–	Sell	-328,824	Closed	-$9.46M	–	223
2020 Q2	$9.46M	Buy	+328,824	New	+$7.61M	0.75%	44

Ikarian Capital's STSA Position: Q2 2023 in Review

Ikarian Capital sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 136,059 shares — an estimated $95K sold.

Ikarian Capital first reported a position in STSA in Q2 2020 and held it in 10 quarters. The position peaked at $9.46M in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

Ikarian Capital reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ikarian Capital sold 136,059 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $95K.
Ikarian Capital first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
Ikarian Capital's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $9.46M in Q2 2020.
0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.